Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding
Cancer Letters · 2025-08 · 624 · 217750
DOI: 10.1016/j.canlet.2025.217750 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-08. Verfasst von Pallab Shaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, 73104, Oklahoma, USA; Department of Pathology,…. Hauptthemen laut MEDLINE: Anoikis, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 548 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Oklahoma Tobacco Settlement Endowment Trust.
Abstract (Originalsprache)
Anoikis, defined as programmed cell death triggered by the loss of cell-extracellular matrix (ECM) and cell-cell interactions, is crucial for maintaining tissue homeostasis and preventing aberrant cell migration. Cancer cells, however, display anoikis resistance (AR) which in turn enables cancer metastasis. AR results from alterations in apoptotic signaling, metabolic reprogramming, autophagy modulation, and epigenetic changes, allowing cancer cells to survive in detached conditions. In this review we describe the mechanisms underlying both anoikis and AR, focusing on intrinsic and extrinsic pathways, disrupted cell-ECM interactions, and autophagy in cancer. Recent findings (i.e., between 2014 and 2024) on epigenetic regulation of AR and its role in metastasis are discussed. Therapeutic strategies targeting AR, including chemical inhibitors, are highlighted alongside a network analysis of 122 proteins reported to be associated with AR which identifies 53 hub proteins as potential targets. We also evaluate in vitro and in vivo models for studying AR, emphasizing their role in advancing metastasis research. Our overall goal is to guide future studies and therapeutic developments to counter cancer metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, 73104, Oklahoma, USA; Department of Pathology, The University of Oklahoma Health Sciences, Oklahoma City, 73104, Okl…
- Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, 73104, Oklahoma, USA; Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences, Oklahoma…
- James E. Hurley School of Science and Mathematics, Oklahoma Baptist University, Shawnee, OK, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- Oklahoma Tobacco Settlement Endowment Trust
- Tobacco Settlement Endowment Trust
Zitieren
APA
Shaw, P., Dey Bhowmik, A., Gopinatha Pillai, M. S., Robbins, N., Dwivedi, S. K. D., & Rao, G. (2025). Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding. Cancer Letters, 624, 217750. https://doi.org/10.1016/j.canlet.2025.217750
Vancouver
Shaw P, Dey Bhowmik A, Gopinatha Pillai MS, Robbins N, Dwivedi SKD, Rao G. Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding. Cancer Letters. 2025;624:217750. doi:10.1016/j.canlet.2025.217750
BibTeX
@article{Shaw2025,
author = {Shaw, Pallab and Dey Bhowmik, Arpan and Gopinatha Pillai, Mohan Shankar and Robbins, Nathan and Dwivedi, Shailendra Kumar Dhar and Rao, Geeta},
title = {Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding},
journal = {Cancer Letters},
year = {2025},
volume = {624},
pages = {217750},
doi = {10.1016/j.canlet.2025.217750}
}
EUVIMED